Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
AVAtea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ · Currency in USD
$4.04 ▼ -0.01 (-0.25%)
At close: Oct 23, 4:00 PM ET. Market closed.
$4.04 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$4.05
Open
$4.03
Day's Range
$3.93 – $4.12
52 Week Range
$2.87 – $6.45
Volume
245,442
Avg. Volume
323,415
Market Cap
$324.03M
Beta (5Y Monthly)
0.29
PE Ratio (TTM)
--
EPS (TTM)
-$2.06
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$7.00

Profile: Atea Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
55
CEO
Jean-Pierre Sommadossi

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.51 · Revenue est. $50.45M
DateEst.Actual
Aug 12, 2026-$0.56-$0.41Beat
May 12, 2026-$0.60-$0.57Beat
Mar 5, 2026-$0.49-$0.57Miss
Nov 12, 2025-$0.46-$0.53Miss
Aug 7, 2025-$0.46-$0.44Beat
May 12, 2025-$0.56-$0.40Beat

Analyst view

Consensus price target
$7.00 ▲ +73.3%
Range $7.00 – $7.00
Rating: Hold
Buy 25% · Hold 50% · Sell 25%

Get free alerts on AVIR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.